Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age

por Yajnik, Vijay, Khan, Nabeel, Dubinsky, Marla, Axler, Jeffrey, James, Alexandra, Abhyankar, Brihad, Lasch, Karen
Publicado 2017

Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial

por Rubin, David T., Cohen, Russell D., Sandborn, William J., Lichtenstein, Gary R., Axler, Jeffrey, Riddell, Robert H., Zhu, Cindy, Barrett, Andrew C., Bortey, Enoch, Forbes, William P.
Publicado 2017

Corrigendum: Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial

por Rubin, David T, Cohen, Russell D, Sandborn, William J, Lichtenstein, Gary R, Axler, Jeffrey, Riddell, Robert H, Zhu, Cindy, Barrett, Andrew C, Bortey, Enoch, Forbes, William P
Publicado 2017

Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis

por Feagan, Brian G, Schreiber, Stefan, Wolf, Douglas C, Axler, Jeffrey L, Kaviya, Arpeat, James, Alexandra, Curtis, Rebecca I, Geransar, Parnia, Stallmach, Andreas, Ehehalt, Robert, Bokemeyer, Bernd, Khalid, Javaria Mona, O’Byrne, Sharon
Publicado 2019

Novel Microbial-Based Immunotherapy Approach for Crohn's Disease

por Sutcliffe, Simon, Kalyan, Shirin, Pankovich, Jim, Chen, Jenny M. H., Gluck, Rashieda, Thompson, Darby, Bosiljcic, Momir, Bazett, Mark, Fedorak, Richard N., Panaccione, Remo, Axler, Jeffrey, Marshall, John K., Mullins, David W., Kabakchiev, Boyko, McGovern, Dermot P. B., Jang, Julie, Coldman, Andrew, Vandermeirsch, Gillian, Bressler, Brian, Gunn, Hal
Publicado 2019